Published in Drug Week, June 10th, 2005
The study found that a combination of Aggrastat and a drug-eluting stent (DES; sirolimus eluting stent) resulted in a significantly lower rate of death, myocardial infarction, stroke, and binary restenosis at 8 months for patients with ST-elevation myocardial infarction (STEMI), while also providing a similar cost of care when compared to abciximab used in combination with a bare metal stent.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.